Annual report pursuant to Section 13 and 15(d)

Segment Information

v3.10.0.1
Segment Information
12 Months Ended
Aug. 31, 2018
Segment Reporting [Abstract]  
Segment Information
16. Segment Information

 

 

The Company’s operations involve the development and usage, including licensing, of its proprietary nutrient infusion Technology. Lexaria is centrally managed and its chief operating decision makers, being the president and the CEO, use the consolidated and other financial information supplemented by revenue information by category of alternative health consumer products and technology licensing to make operational decisions and to assess the performance of the Company. The company has identified two reportable segments: Intellectual Property Licensing and Consumer Products. Licensing revenues are significantly concentrated on five licensees.

 

 

 

IP

Licensing

 

 

Consumer

Products

 

 

Corporate

 

 

Consolidated

Total

 

External Revenue

 

 

 

 

 

 

 

 

 

 

 

 

US

 

 

240,183

 

 

 

18,104

 

 

 

-

 

 

 

 

Canada

 

 

175,000

 

 

 

-

 

 

 

-

 

 

 

433,287

 

CoGS

 

 

-

 

 

 

(25,185)

 

 

 

-

 

 

 

(25,185)

 

Operating Expenses

 

 

(2,237,598 )

 

 

150,040

 

 

 

(4,629,651 )

 

 

7,017,289

 

Segment Loss

 

 

(1,822,415 )

 

 

(157,121 )

 

 

(4,629,651 )

 

 

(6,609,187 )

Total Assets

 

 

345,913

 

 

 

88,470

 

 

 

1,997,443

 

 

 

2,431,826